Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARD-501

Other · developed by Aardvark Therapeutics

Phase 2 Most advanced trial (none active)
AARD Developer
1 Registered trials

What is ARD-501?

ARD-501 is an investigational drug studied in Autism Spectrum Disorder.

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
Aardvark Therapeutics, Inc. (AARD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06126653 Phase 2 Autism Spectrum Disorder Completed AARD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autism Spectrum Disorder

More from Aardvark Therapeutics

ARD-101 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AARD page.

Follow AARD, the company behind ARD-501

See AARD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AARD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.